Question: Passage: You are caring for a 42-year-old female patient with triple-negative breast cancer (TNBC - negative for oestrogen and progesterone receptors, and HER2) and a germline BRCA1 mutation. Upon completing the standard chemotherapy regimen, her cancer continued to grow, indicating disease progression. Biopsies indicated her tumour remains HER2-negative, and she had no history of kidney or liver abnormalities. She also recently completed radiotherapy for bone metastases. Shortly after, she began experiencing acute, severe pain that was unresponsive to high-dose paracetamol and opioids. The pain was described as burning and shooting, localised to the irradiated area. Without success from the traditional therapy, the oncology team decided to apply a novel targeted therapy, Drug X, for her, and has been monitoring her closely for toxicity. They also initiated pregabalin, an antiepileptic drug, to manage her pain. The patient's BRCA1 mutation makes her particularly sensitive to which of the following targeted therapies (i.e. identify the Drug X)? Question options: Trastuzumab (HER2 monoclonal antibody) Olaparib (PARP inhibitor -- induces synthetic lethality) Ado-Trastuzumab (HER2-targeted antibody-drug conjugate) Abiraterone (androgen synthesis inhibitor). Need Assignment Help?